Wuhan Yzy Biopharma Co., Ltd.
Clinical trials sponsored by Wuhan Yzy Biopharma Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody drug targets Cancer-Related fluid in the lungs Results expected Sep 2026 (estimated)
-
New drug cocktail shows promise against tough pancreatic cancer
Disease control CompletedThis completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumo…
Phase 1/2 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug M701 aims to stop Cancer-Related fluid buildup without drains
Symptom relief CompletedThis study tested a drug called M701, given directly into the belly, combined with standard cancer therapy, for people with malignant ascites (fluid buildup) from stomach, colon, or ovarian cancer. The goal was to see if M701 could delay the need for fluid drainage and improve su…
Phase 2 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC